Tumor associated antigens are appropriate targets for radio- immunoconjugate therapy with monoclonal antibodies. Gastrointestinal adenocarcinomas are shown to be rich in glycoprotein antigens including the TAG-72 antigen. The TAG-72 antigen is a unique tumor associated antigen, which was originally defined by monoclonal antibody (MAb) B72.3. Second of these antibodies (MAb CC49) also exhibits high levels of binding to gastrointestinal tract cancers and has eight-fold greater affinity than MAb B72.3 for the TAG-72 antigen. Phase I trails using 1311 labeled or 90Yttrium conjugated MAb CC49 have been conducted using hematopoietic stem cell support to escalate dose. While absorbed doses in metastatic tumor sites of up to 3300 cGy have been observed, several obstacles to optimizing therapy have been encountered. In this project, we describe a series of studies designed to improve radio- immunotherapy with MAb CC49, which is predicted to be less immunogenic. These trails will explore diodistribution and pharmacokinetics of this construct and the possibility of multi-dose treatment strategies. Preclinical studies are planned with 47Scandium conjugated hCC49deltaCH2 to evaluate the best chalet, dose and schedule of administration in preparation for one of the proposed clinical trails. A dosimetry program will support the clinical studies in the conduct of all the clinical trails and will establish important new methods for dosimetry estimation using 47Scandium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA072712-03S3
Application #
6444611
Study Section
Project Start
1999-03-25
Project End
2003-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
2001
Total Cost
$201,603
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
City
Omaha
State
NE
Country
United States
Zip Code
68198
Chan, June M; Gong, Zhihong; Holly, Elizabeth A et al. (2013) Dietary patterns and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area. Nutr Cancer 65:157-64
Mutolo, Michael J; Morris, Kirsten J; Leir, Shih-Hsing et al. (2012) Tumor suppression by collagen XV is independent of the restin domain. Matrix Biol 31:285-9
Pour, Parviz M (2012) A novel tissue for islet transplantation in diabetics. Pancreatology 12:57-60
Sherman, Simon; Shats, Oleg; Ketcham, Marsha A et al. (2011) PCCR: Pancreatic Cancer Collaborative Registry. Cancer Inform 10:83-91
Chan, June M; Wang, Furong; Holly, Elizabeth A (2009) Sweets, sweetened beverages, and risk of pancreatic cancer in a large population-based case-control study. Cancer Causes Control 20:835-46
Moniaux, Nicolas; Nemos, Christophe; Deb, Shonali et al. (2009) The human RNA polymerase II-associated factor 1 (hPaf1): a new regulator of cell-cycle progression. PLoS One 4:e7077
Mimeault, M; Hauke, R; Batra, S K (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83:673-91
Hennig, R; Osman, T; Esposito, I et al. (2008) BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. Br J Cancer 99:1064-73
Davda, Jasmine P; Jain, Maneesh; Batra, Surinder K et al. (2008) A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8:401-13
Hennig, Rene; Kehl, Timo; Noor, Seema et al. (2007) 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia 9:917-26

Showing the most recent 10 out of 108 publications